```
                  STN Express with Discover!
 NEWS  4  OCT 28  KOREAPAT now available on STN
 NEWS  5  NOV 30  PHAR reloaded with additional data
 NEWS  6  DEC 01  LISA now available on STN
 NEWS  7  DEC 09  12 databases to be removed from STN on December 31, 2004
 NEWS  8  DEC 15  MEDLINE update schedule for December 2004
 NEWS  9  DEC 17  ELCOM reloaded; updating to resume; current-awareness
                  alerts (SDIs) affected
 NEWS  10 DEC 17  COMPUAB reloaded; updating to resume; current-awareness
                  alerts (SDIs) affected
 NEWS  11 DEC 17  SOLIDSTATE reloaded; updating to resume; current-awareness
                  alerts (SDIs) affected
 NEWS  12 DEC 17  CERAB reloaded; updating to resume; current-awareness
                  alerts (SDIs) affected
 NEWS  13 DEC 17  THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
 NEWS  14 DEC 30  EPFULL: New patent full text database to be available on STN
 NEWS  15 DEC 30  CAPLUS - PATENT COVERAGE EXPANDED
 NEWS  16 JAN 03  No connect-hour charges in EPFULL during January and
                  February 2005
 NEWS  17 FEB 25  CA/CAPLUS - Russian Agency for Patents and Trademarks
                  (ROSPATENT) added to list of core patent offices covered
 NEWS  18 FEB 10  STN Patent Forums to be held in March 2005
 NEWS  19 FEB 16  STN User Update to be held in conjunction with the 229th ACS
                  National Meeting on March 13, 2005

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:01:10 ON 28 FEB 2005

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:01:21 ON 28 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 FEB 2005  HIGHEST RN 838086-80-9
DICTIONARY FILE UPDATES:  25 FEB 2005  HIGHEST RN 838086-80-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s testosterone/cn
L1 1 TESTOSTERONE/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 58-22-0 REGISTRY
CN Androst-4-en-3-one, 17-hydroxy-, (17β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Testosterone (7CI, 8CI)**
OTHER NAMES:
CN Δ4-Androsten-17β-ol-3-one
CN 17β-Hydroxy-Δ4-androsten-3-one
CN 17β-Hydroxyandrost-4-en-3-one
CN 17β-Hydroxyandrost-4-ene-3-one
CN 17β-Testosterone
CN 4-Androsten-3-one-17β-ol
CN AA 2500
CN Andro 100
CN Androderm
CN AndroGel
CN Androlin
CN Andronaq
CN Andropatch
CN Androst-4-en-17β-ol-3-one
CN Androst-4-ene-17β-ol-3-one
CN Androsol
CN CDB 111C
CN COL 1621
CN CP 601B
CN Cristerona T
CN Geno-cristaux Gremy
CN Homosteron
CN Homosterone
CN Mertestate
CN Neotestis
CN NSC 9700
CN Oreton
CN Orquisteron
CN Perandren
CN Percutacrine androgenique
CN Primotest
CN Primoteston
CN Relibra
CN Sustanon
CN Sustanone
CN Sustason 250
CN Synandrol F
CN Teslen
CN Testandrone
CN Testiculosterone
CN Testim
CN Testobase
CN Testoderm
CN Testogel
CN Testolent
CN Testolin
CN Testopropon
CN Testosteroid
CN Testosteron
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

FS STEREOSEARCH
MF C19 H28 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent; Preprint; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

41219 REFERENCES IN FILE CA (1907 TO DATE)
505 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
41255 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file usepatful
'USEPATFUL' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> s l1
L2 1 TESTOSTERONE/CN

=> file uspatful

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.90	12.11

```
FILE 'USPATFULL' ENTERED AT 09:02:20 ON 28 FEB 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Feb 2005 (20050224/PD)
FILE LAST UPDATED: 24 Feb 2005 (20050224/ED)
HIGHEST GRANTED PATENT NUMBER: US6859937
HIGHEST APPLICATION PUBLICATION NUMBER: US2005044601
CA INDEXING IS CURRENT THROUGH 24 Feb 2005 (20050224/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Feb 2005 (20050224/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2004
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2004

>>>  USPAT2 is now available.  USPATFULL contains full text of the     <<<
>>>  original, i.e., the earliest published granted patents or         <<<
>>>  applications.  USPAT2 contains full text of the latest US         <<<
>>>  publications, starting in 2001, for the inventions covered in     <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original     <<<
>>>  published document but also a list of any subsequent              <<<
>>>  publications.  The publication number, patent kind code, and      <<<
>>>  publication date for all the US publications for an invention     <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL   <<<
>>>  records and may be searched in standard search fields, e.g., /PN, <<<
>>>  /PK, etc.                                                         <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together        <<<
>>>  through the new cluster USPATALL.  Type FILE USPATALL to          <<<
>>>  enter this cluster.                                               <<<
>>>                                                                    <<<
>>>  Use USPATALL when searching terms such as patent assignees,       <<<
>>>  classifications, or claims, that may potentially change from      <<<
>>>  the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l1
L3          985 L1

=> s l3 and prostatic (w) hyperlasia
           9320 PROSTATIC
             48 HYPERLASIA
              1 HYPERLASIAS
             49 HYPERLASIA
                (HYPERLASIA OR HYPERLASIAS)
             21 PROSTATIC (W) HYPERLASIA
L4            1 L3 AND PROSTATIC (W) HYPERLASIA

=> d

L4   ANSWER 1 OF 1  USPATFULL on STN
AN     93:98371  USPATFULL
TI     20-substituted pregnene derivatives and their use as androgen synthesis
       inhibitors
IN     Brodie, Angela, Fulton, MD, United States
       Li, Jisong, Baltimore, MD, United States
PA     Research Corporation Technologies, Inc., Tuscon, AZ, United States (U.S.
       corporation)
PI     US 5264427              19931123
AI     US 1992-827040          19920129 (7)
DT     Utility
FS     Granted
LN.CNT 819
INCL   INCLM: 514/177.000
       INCLS: 552/601.000; 552/602.000
NCL    NCLM:  514/177.000
       NCLS:  552/601.000; 552/602.000
IC     [5]
       ICM: A61K031-56
```

EXF 514/177; 514/172; 552/601; 552/602
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l3 and prostatic (w) hypertrophy
9320 PROSTATIC
9303 HYPERTROPHY
194 HYPERTROPHIES
9358 HYPERTROPHY
(HYPERTROPHY OR HYPERTROPHIES)
2765 PROSTATIC (W) HYPERTROPHY
L5 42 L3 AND PROSTATIC (W) HYPERTROPHY

=> d 21-42

L5 ANSWER 21 OF 42 USPATFULL on STN
AN 2000:138366 USPATFULL
TI Androgen synthesis inhibitors
IN Brodie, Angela, Fulton, MD, United States
Ling, Yangzhi, Beijing, China
PA University of Maryland at Baltimore, Baltimore, MD, United States (U.S. corporation)
PI US 6133280 20001017
AI US 1999-307714 19990510 (9)
RLI Division of Ser. No. US 1997-795932, filed on 5 Feb 1997, now patented, Pat. No. US 5994334
DT Utility
FS Granted
LN.CNT 1438
INCL INCLM: 514/284.000
INCLS: 514/176.000; 514/261.000; 514/262.000; 514/256.000; 514/269.000; 514/253.000; 544/264.000; 544/265.000; 544/298.000; 540/004.000
NCL NCLM: 514/284.000
NCLS: 514/176.000; 514/183.000; 514/253.020; 514/256.000; 514/269.000; 540/004.000; 544/264.000; 544/265.000; 544/298.000
IC [7]
ICM: A61K031-715
ICS: C07J043-00
EXF 514/284; 546/77
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 42 USPATFULL on STN
AN 2000:109794 USPATFULL
TI Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
IN Sullivan, David A., Acton, MA, United States
PA The Schepens Eye Research Institute, Inc., Boston, MA, United States (U.S. corporation)
PI US 6107289 20000822
AI US 1999-271600 19990317 (9)
RLI Continuation-in-part of Ser. No. US 1997-971768, filed on 17 Nov 1997, now patented, Pat. No. US 5958912 which is a continuation-in-part of Ser. No. US 1995-477301, filed on 7 Jun 1995, now patented, Pat. No. US 5688765 which is a continuation-in-part of Ser. No. US 1993-124842, filed on 21 Sep 1993, now patented, Pat. No. US 5620921 which is a continuation of Ser. No. US 1992-871657, filed on 21 Apr 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1782
INCL INCLM: 514/178.000
INCLS: 514/912.000
NCL NCLM: 514/178.000
NCLS: 514/912.000
IC [7]
ICM: A61K031-56
EXF 514/178; 514/912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 42 USPATFULL on STN
AN 2000:18453 USPATFULL
TI Method for treating the symptoms of chronic stress-related disorders using IGF
IN Mascarenhas, Desmond, Los Altos Hills, CA, United States
Sanders, Martin, Hillsborough, CA, United States
PA Celtrix Pharmaceuticals, Inc., San Jose, CA, United States (U.S. corporation)
PI US 6025368 20000215
AI US 1997-805807 19970225 (8)
DT Utility
FS Granted
LN.CNT 1085
INCL INCLM: 514/310.000
INCLS: 514/002.000; 514/012.000; 435/069.100; 530/333.000; 530/324.000; 530/303.000
NCL NCLM: 514/310.000
NCLS: 435/069.100; 514/002.000; 514/012.000; 530/303.000; 530/324.000; 530/333.000
IC [7]
ICM: A01N043-42
EXF 435/69.1; 514/2; 514/12; 350/333; 350/324; 350/303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 42 USPATFULL on STN
AN 1999:155717 USPATFULL
TI Androgen synthesis inhibitors
IN Brodie, Angela, Fulton, MD, United States
Ling, Yangzhi, Beijing, China
PA University of Maryland, Baltimore, MD, United States (U.S. corporation)
PI US 5994334 19991130
AI US 1997-795932 19970205 (8)
DT Utility
FS Granted
LN.CNT 1465
INCL INCLM: 514/176.000
INCLS: 540/096.000
NCL NCLM: 514/176.000
NCLS: 540/096.000
IC [6]
ICM: A61K031-58
ICS: C07J043-00
EXF 540/96; 514/176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 42 USPATFULL on STN
AN 1999:132805 USPATFULL
TI Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
IN Santti, Risto, Naantali, Finland
Talo, Antti, Littoinen, Finland
Streng, Tomi, Turku, Finland
Halonen, Kaija, Rusko, Finland
Kangas, Lauri, Raisio, Finland
Lammintausta, Risto, Turku, Finland
PA Hormos Medical Oy Ltd., Turku, Finland (non-U.S. corporation)
PI US 5972921 19991026
AI US 1997-989447 19971212 (8)
DT Utility
FS Granted
LN.CNT 962
INCL INCLM: 514/177.000
INCLS: 514/179.000; 514/300.000; 514/318.000; 514/383.000
NCL NCLM: 514/177.000
NCLS: 514/179.000; 514/300.000; 514/318.000; 514/383.000
IC [6]
ICM: A61K031-56
ICS: A61K031-44; A61K031-445; A61K031-41
EXF 514/383; 514/300; 514/318; 514/177; 514/179

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 42 USPATFULL on STN
AN 1998:33599 USPATFULL
TI Male contraceptive implant
IN Moo-Young, Alfred J., Hastings-on-Hudson, NY, United States
Saleh, Saleh I., Queens, NY, United States
PA The Population Council, Center for Biomedical Research, New York, NY, United States (U.S. corporation)
PI US 5733565 19980331
AI US 1996-606063 19960223 (8)
DT Utility
FS Granted
LN.CNT 964
INCL INCLM: 424/424.000
INCLS: 514/772.300
NCL NCLM: 424/424.000
NCLS: 514/772.300
IC [6]
ICM: A61F002-02
ICS: A61K047-32
EXF 424/423; 424/424; 514/772.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 42 USPATFULL on STN
AN 96:16991 USPATFULL
TI Inhibitors for testosterone 5α-reductase activity
IN Labrie, Fernand, Ste-Foy, Canada
Merand, Yves M., Ste-Foy, Canada
Singh, Shankar M., Ste-Foy, Canada
PA Endorecherche, Canada (non-U.S. corporation)
PI US 5494914 19960227
AI US 1994-196332 19940214 (8)
RLI Division of Ser. No. US 1992-886961, filed on 21 May 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1831
INCL INCLM: 514/284.000
INCLS: 514/859.000; 514/864.000
NCL NCLM: 514/284.000
NCLS: 514/859.000; 514/864.000
IC [6]
ICM: A61K031-44
EXF 514/284; 514/859; 514/864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 42 USPATFULL on STN
AN 93:98371 USPATFULL
TI 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
IN Brodie, Angela, Fulton, MD, United States
Li, Jisong, Baltimore, MD, United States
PA Research Corporation Technologies, Inc., Tuscon, AZ, United States (U.S. corporation)
PI US 5264427 19931123
AI US 1992-827040 19920129 (7)
DT Utility
FS Granted
LN.CNT 819
INCL INCLM: 514/177.000
INCLS: 552/601.000; 552/602.000
NCL NCLM: 514/177.000
NCLS: 552/601.000; 552/602.000
IC [5]
ICM: A61K031-56
EXF 514/177; 514/172; 552/601; 552/602
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 29 OF 42 USPATFULL on STN

AN 92:10866 USPATFULL
TI Method of controlling T.sub.3 and T.sub.4 levels in vivo with cobalt porphyrins
IN Kappas, Attallah, New York, NY, United States
Drummond, George S., New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5087622 19920211
AI US 1990-498275 19900323 (7)
RLI Continuation-in-part of Ser. No. US 1989-310855, filed on 14 Feb 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-105591, filed on 13 Nov 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-927830, filed on 6 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-832512, filed on 21 Feb 1986, now abandoned which is a continuation of Ser. No. US 1985-708228, filed on 5 Mar 1985, now abandoned which is a continuation-in-part of Ser. No. US 1982-363588, filed on 30 Mar 1982, now abandoned
DT Utility
FS Granted
LN.CNT 495
INCL INCLM: 514/185.000
INCLS: 514/410.000
NCL NCLM: 514/185.000
NCLS: 514/410.000
IC [5]
ICM: A61K031-40
EXF 514/185.41
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 30 OF 42 USPATFULL on STN
AN 92:7364 USPATFULL
TI Methods for suppressing the endocrine system
IN Kappas, Attallah, New York, NY, United States
Drummond, George S., New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5084475 19920128
AI US 1990-498274 19900323 (7)
RLI Division of Ser. No. US 1989-310855, filed on 14 Feb 1989, now patented, Pat. No. US 4948792 which is a continuation-in-part of Ser. No. US 1987-105591, filed on 13 Nov 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-927830, filed on 6 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-832512, filed on 21 Feb 1986, now abandoned which is a continuation of Ser. No. US 1985-708228, filed on 5 Mar 1985, now abandoned which is a continuation-in-part of Ser. No. US 1982-363588, filed on 30 Mar 1982, now abandoned
DT Utility
FS Granted
LN.CNT 476
INCL INCLM: 514/410.000
INCLS: 514/185.000; 514/910.000
NCL NCLM: 514/410.000
NCLS: 514/185.000; 514/910.000
IC [5]
ICM: A61K031-40
ICS: A61K031-555
EXF 514/185; 514/410; 514/910
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 31 OF 42 USPATFULL on STN
AN 91:94548 USPATFULL
TI Method for suppressing the endocrine system
IN Kappas, Attallah, New York, NY, United States
Drummond, George S., New York, NY, United States
PA The Rockefeller University, NY, United States (U.S. corporation)
PI US 5066650 19911119
AI US 1991-638623 19910108 (7)

RLI Division of Ser. No. US 1990-498289, filed on 23 Mar 1990 which is a continuation-in-part of Ser. No. US 1987-105591, filed on 13 Nov 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-927830, filed on 6 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-832512, filed on 21 Feb 1986, now abandoned And a continuation of Ser. No. US 1985-708228, filed on 5 Mar 1985, now abandoned which is a continuation-in-part of Ser. No. US 1982-363588, filed on 30 Mar 1982, now abandoned
DT Utility
FS Granted
LN.CNT 482
INCL INCLM: 514/185.000
INCLS: 514/410.000
NCL NCLM: 514/185.000
NCLS: 514/410.000
IC [5]
ICM: A61K031-555
EXF 514/185; 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 32 OF 42 USPATFULL on STN
AN 91:90757 USPATFULL
TI Method of controlling androstene levels in vivo with cobalt porphyrins
IN Kappas, Attallah, New York, NY, United States
Drummond, George S., New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 5063223 19911105
AI US 1990-498289 19900323 (7)
RLI Division of Ser. No. US 1989-310855, filed on 14 Feb 1989, now patented, Pat. No. US 4948792 which is a continuation-in-part of Ser. No. US 1987-105591, filed on 13 Nov 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-927830, filed on 6 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-832512, filed on 21 Feb 1986, now abandoned which is a continuation of Ser. No. US 1985-708228, filed on 5 Mar 1985, now abandoned which is a continuation-in-part of Ser. No. US 1982-363588, filed on 8 Mar 1982, now abandoned
DT Utility
FS Granted
LN.CNT 488
INCL INCLM: 514/185.000
INCLS: 514/410.000
NCL NCLM: 514/185.000
NCLS: 514/410.000
IC [5]
ICM: A61K031-40
EXF 514/185; 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 33 OF 42 USPATFULL on STN
AN 90:63515 USPATFULL
TI Methods for suppressing the endocrine system
IN Kappas, Attallah, New York, NY, United States
Drummond, George S., New York, NY, United States
PA The Rockefeller University, New York, NY, United States (U.S. corporation)
PI US 4948792 19900814
AI US 1989-310855 19890214 (7)
RLI Continuation-in-part of Ser. No. US 1987-105591, filed on 13 Nov 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-927830, filed on 6 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-832512, filed on 21 Feb 1986, now abandoned which is a continuation of Ser. No. US 1985-708228, filed on 5 Mar 1985, now abandoned which is a continuation-in-part of Ser. No. US 1982-363588, filed on 30 Mar 1982, now abandoned
DT Utility
FS Granted
LN.CNT 468

INCL INCLM: 514/185.000
INCLS: 514/410.000
NCL NCLM: 514/185.000
NCLS: 514/410.000
IC [5]
ICM: A61K031-40
ICS: A61K031-555
EXF 514/410; 514/185
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 34 OF 42 USPATFULL on STN
AN 87:81469 USPATFULL
TI Methods, compositions and compounds for the treatment of prostatic adenoma
IN Bombardelli, Ezio, Milan, Italy
Gabetta, Bruno, Milan, Italy
Conti, Marisa, Milan, Italy
PA Inverni Della Beffa SpA, Milan, Italy (non-U.S. corporation)
PI US 4709076 19871124
AI US 1985-743073 19850610 (6)
PRAI IT 1984-21342 19840611
DT Utility
FS Granted
LN.CNT 330
INCL INCLM: 560/055.000
INCLS: 514/532.000; 560/104.000
NCL NCLM: 560/055.000
NCLS: 560/104.000
IC [4]
ICM: C07C069-76
EXF 560/55; 560/104; 514/532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 35 OF 42 USPATFULL on STN
AN 83:11252 USPATFULL
TI 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
IN Rasmusson, Gary H., Watchung, NJ, United States
Johnston, David B. R., Warren, NJ, United States
Arth, deceased, Glen E., late of Cranford, NJ, United States by Rose B. Arth, executrix
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4377584 19830322
AI US 1980-189981 19800923 (6)
RLI Continuation-in-part of Ser. No. US 1979-20371, filed on 15 Mar 1979, now abandoned which is a continuation-in-part of Ser. No. US 1978-896118, filed on 13 Apr 1978, now abandoned
DT Utility
FS Granted
LN.CNT 899
INCL INCLM: 424/258.000
INCLS: 260/239.000BB; 260/239.300P; 424/244.000; 546/077.000; 546/078.000
NCL NCLM: 514/284.000
NCLS: 514/212.040; 514/859.000; 514/864.000; 540/576.000; 546/015.000; 546/077.000; 546/078.000; 546/152.000
IC [3]
ICM: A61K031-395
ICS: A61K031-47; C07D221-18
EXF 546/77; 546/78; 260/239BB; 260/239.3P; 424/244; 424/258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 36 OF 42 USPATFULL on STN
AN 82:10024 USPATFULL
TI Novel steroid 5α-reductase inhibitors
IN Blohm, Thomas R., Cincinnati, OH, United States
Metcalf, Brian W., Mason, OH, United States
PA Richardson-Merrell Inc., Wilton, CT, United States (U.S. corporation)
PI US 4317817 19820302
AI US 1980-216112 19801215 (6)

RLI Continuation-in-part of Ser. No. US 1979-69741, filed on 27 Aug 1979, now abandoned which is a continuation-in-part of Ser. No. US 1979-35357, filed on 2 May 1979, now abandoned
DT Utility
FS Granted
LN.CNT 949
INCL INCLM: 424/226.000
INCLS: 260/349.000; 260/397.500; 260/397.400; 260/239.550C; 260/397.100; 260/239.550R
NCL NCLM: 514/150.000
NCLS: 534/556.000; 552/505.000; 552/516.000; 552/555.000; 552/603.000; 552/611.000; 552/635.000
IC [3]
ICM: A01N047-08
ICS: A61K031-655
EXF 260/349; 424/243; 424/226
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 37 OF 42 USPATFULL on STN
AN 80:43148 USPATFULL
TI Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
IN Rasmusson, Gary H., Watchung, NJ, United States
Johnston, David B. R., Warren, NJ, United States
Reinhold, Donald F., North Plainfield, NJ, United States
Utne, Torleif, Warren, NJ, United States
Jobson, Ronald B., East Brunswick, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4220775 19800902
AI US 1979-20372 19790315 (6)
DT Utility
FS Granted
LN.CNT 888
INCL INCLM: 546/077.000
INCLS: 260/239.300P; 260/397.400; 260/397.100; 260/397.300; 424/263.000; 424/244.000; 260/397.500; 549/039.000
NCL NCLM: 546/077.000
NCLS: 514/859.000; 540/519.000; 546/015.000; 549/039.000; 552/510.000; 552/519.000; 552/611.000; 552/641.000; 552/650.000
IC [2]
ICM: C07D221-18
EXF 546/77; 260/239.3P
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 38 OF 42 USPATFULL on STN
AN 79:51001 USPATFULL
TI Process for preparing 17β-carboxy-5-androsten-3-ones
IN Johnston, David B. R., Warren, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4179453 19791218
AI US 1978-896120 19780413 (5)
DT Utility
FS Granted
LN.CNT 226
INCL INCLM: 260/397.100
INCLS: 260/239.500
NCL NCLM: 552/611.000
NCLS: 540/111.000
IC [2]
ICM: C07J009-00
EXF 260/397.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 39 OF 42 USPATFULL on STN
AN 78:13014 USPATFULL
TI Method of inducing an estrogenic response
IN Benson, Harvey D., Cincinnati, OH, United States
Grunwell, Joyce Francis, Hamilton, OH, United States
Johnston, John O'Neal, Cincinnati, OH, United States

Petrow, Vladimir, Chapel Hill, NC, United States
PA Richardson-Merrell Inc., Wilton, CT, United States (U.S. corporation)
PI US 4078060 19780307
AI US 1976-684944 19760510 (5)
DT Utility
FS Granted
LN.CNT 769
INCL INCLM: 424/242.000
INCLS: 424/243.000
NCL NCLM: 514/177.000
NCLS: 514/178.000
IC [2]
ICM: A61K031-56
EXF 424/242; 424/243
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 40 OF 42 USPATFULL on STN
AN 76:50617 USPATFULL
TI Testosterone derivatives
IN Babcock, John C., Kalamazoo, MI, United States
Campbell, J. Allan, Kalamazoo, MI, United States
PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI US 3980638 19760914
AI US 1974-507690 19740920 (5)
DT Utility
FS Granted
LN.CNT 256
INCL INCLM: 260/239.550R
INCLS: 260/397.400; 260/239.550R; 424/241.000
NCL NCLM: 540/057.000
NCLS: 552/527.000; 552/635.000; 552/638.000; 552/639.000; 552/641.000
IC [2]
ICM: C07J017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 41 OF 42 USPATFULL on STN
AN 75:59666 USPATFULL
TI 3-Keto-7 α,β-loweralkyl-Δ 5-steroids
IN Grunwell, Joyce F., Cincinnati, OH, United States
Benson, Harvey D., Cincinnati, OH, United States
Petrow, Vladimir, Cincinnati, OH, United States
PA Richardson-Merrell Inc., Wilton, CT, United States (U.S. corporation)
PI US 3917831 19751104
AI US 1974-476330 19740604 (5)
RLI Division of Ser. No. US 1972-236186, filed on 20 Mar 1972, now patented, Pat. No. US 3833621
DT Utility
FS Granted
LN.CNT 1449
INCL INCLM: 424/243.000
INCLS: 424/241.000; 424/242.000
NCL NCLM: 514/178.000
NCLS: 514/177.000; 514/179.000
IC [2]
ICM: A61K031-56
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 42 OF 42 USPATFULL on STN
AN 74:42135 USPATFULL
TI 3'-KETO-2',3'-SECO-1'-(2')-YNE STEROIDAL DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND COMPOUNDS PRODUCED THEREBY
IN Tanabe, Masato, Palo Alto, CA, United States
PA Schering Corporation, Bloomfield, NJ, United States (U.S. corporation)
PI US 3835160 19740910
AI US 1967-647315 19670620 (4)
RLI Continuation-in-part of Ser. No. US 1967-644761, filed on 6 Jun 1967, now abandoned
DT Utility
FS Granted

LN.CNT 3192
INCL INCLM: 260/340.900
INCLS: 260/239.550R; 260/239.550C; 260/340.500; 260/345.800;
260/345.900; 260/397.100; 260/397.400; 260/488.000B; 260/586.000H
NCL NCLM: 549/334.000
NCLS: 540/007.000; 540/008.000; 540/012.000; 540/014.000; 540/020.000;
540/023.000; 540/031.000; 540/076.000; 540/078.000; 540/079.000;
540/080.000; 540/083.000; 549/336.000; 549/339.000; 549/421.000;
552/508.000; 552/518.000; 552/526.000; 552/572.000; 552/577.000;
552/581.000; 552/590.000; 552/594.000; 552/595.000; 552/597.000;
552/598.000; 552/607.000; 552/632.000; 552/633.000; 552/635.000;
552/638.000; 552/639.000; 552/641.000; 552/646.000; 560/256.000;
568/343.000; 568/373.000; 568/374.000
IC [1]
ICM: C07D013-04
EXF 260/340.9; 260/340.5; 260/345.8; 260/345.9; 260/488; 260/586H
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file caplus medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.10	48.21

FILE 'CAPLUS' ENTERED AT 09:08:05 ON 28 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'MEDLINE' ENTERED AT 09:08:05 ON 28 FEB 2005

=> s l1
L6 87202 L1

=> s l6 and prostatic (w) (hyperlasia or hypertrophy)
L7 210 L6 AND PROSTATIC (W) (HYPERLASIA OR HYPERTROPHY)

=> s l6 and prostatic (w) (hyperlasia or hypertrophy)/ti
L8 86 L6 AND PROSTATIC (W) (HYPERLASIA OR HYPERTROPHY)/TI

=> s l8 and testosterone/ti
L9 28 L8 AND TESTOSTERONE/TI

=> duplicate remove l9
DUPLICATE PREFERENCE IS 'CAPLUS, MEDLINE'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L9
L10 20 DUPLICATE REMOVE L9 (8 DUPLICATES REMOVED)

=> d ibib abs 11-20

L10 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 1975:456403 CAPLUS
DOCUMENT NUMBER: 83:56403
TITLE: Systematic study of **testosterone** metabolism in benign **prostatic hypertrophy** (BPH). In vitro results
AUTHOR(S): Altwein, J. E.; Orestano, F.
CORPORATE SOURCE: Urol. Universitaets-Klin., Mainz, Fed. Rep. Ger.
SOURCE: Urological Research (1975), 2(4), 143-8
CODEN: URLRA5; ISSN: 0300-5623
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An in vitro system for testing steroids which might be effective in treating benign prostatic hypertrophy (BPH) was developed based upon the transformation of testosterone-3H into the 5α-reduction products, dihydrotestosterone and 3α-androstanediol. The testosterone-3H concentration was varied from 0.17-100 + 108M. The rate of testosterone-3H metabolism could not be enhanced after the endogenous testosterone content

within the prostate glands was exhausted in the preincubation. Heparin, a weak nonspecific enzyme inhibitor, did not suppress the appearance of 5α-reduction products. However, damage of the BPH-cells by repetitive freezing and thawing lead to inhibition of testosterone-3H turnover.

L10 ANSWER 12 OF 20 MEDLINE on STN
ACCESSION NUMBER: 74302662 MEDLINE
DOCUMENT NUMBER: PubMed ID: 4136809
TITLE: In vitro studies of **testosterone** and 5alpha-dihydrotestosterone binding in benign **prostatic hypertrophy.**
AUTHOR: Steins P; Krieg M; Hollmann H J; Voigt K D
SOURCE: Acta endocrinologica, (1974 Apr) 75 (4) 773-84. Journal code: 0370312. ISSN: 0001-5598.
PUB. COUNTRY: Denmark
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197411
ENTRY DATE: Entered STN: 19900310
Last Updated on STN: 19900310
Entered Medline: 19741118

L10 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 1974:546078 CAPLUS
DOCUMENT NUMBER: 81:146078
TITLE: **Testosterone** metabolism in benign **prostatic hypertrophy.** Suppression by diethylstilbestrol and gestonorone carpronate
AUTHOR(S): Orestano, F.; Klose, K.; Rubin, A.; Knapstein, P.; Altwein, J. E.
CORPORATE SOURCE: Med. Sch., Univ. Mainz, Mainz, Fed. Rep. Ger.
SOURCE: Investigative Urology (1974), 12(2), 151-6 CODEN: INURAQ; ISSN: 0021-0005
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The effect of diethylstilbestrol [56-53-1] and gestonorone capronate (I) [1253-28-7] on the turnover rate of testosterone [**58-22-0**] into 5α-dihydrotestosterone in human benign prostatic hypertrophy (BPH) was examined in vitro in various concns. Diethylstilbestrol did not influence the testosterone metabolism significantly. I, however, was effective in decreasing the 5α-dihydrotestosterone formation in very low concns. Due to this mechanism I could halt the growth of BPH when used therapeutically.

L10 ANSWER 14 OF 20 MEDLINE on STN
ACCESSION NUMBER: 73240139 MEDLINE
DOCUMENT NUMBER: PubMed ID: 4125280
TITLE: In-vitro studies on **testosterone** and 5alpha-dihydrotestosterone binding in benign **prostatic hypertrophy** (BPH).
AUTHOR: Steins P; Hollmann H J; Schmidt H; Voigt K D
SOURCE: Acta endocrinologica. Supplementum, (1973) 173 69. Journal code: 0370313. ISSN: 0300-9750.
PUB. COUNTRY: Denmark
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197310
ENTRY DATE: Entered STN: 19900310
Last Updated on STN: 19900310
Entered Medline: 19731025

L10 ANSWER 15 OF 20 MEDLINE on STN
ACCESSION NUMBER: 73041999 MEDLINE
DOCUMENT NUMBER: PubMed ID: 4117573
TITLE: In vivo uptake and metabolism of 3H-**testosterone** and 3H-5 -dihydrotestosterone by human benign **prostatic hypertrophy.**

AUTHOR: Becker H; Kaufmann J; Klosterhalfen H; Voigt K D
SOURCE: Acta endocrinologica, (1972 Nov) 71 (3) 589-99.
Journal code: 0370312. ISSN: 0001-5598.
PUB. COUNTRY: Denmark
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197301
ENTRY DATE: Entered STN: 19900310
Last Updated on STN: 19900310
Entered Medline: 19730118

L10 ANSWER 16 OF 20 MEDLINE on STN
ACCESSION NUMBER: 71152618 MEDLINE
DOCUMENT NUMBER: PubMed ID: 4101325
TITLE: **Testosterone** metabolism in human prostatic tissue and blood in patients with benign **prostatic hypertrophy** (BPH).
AUTHOR: Becker H; Buric L; Petersen C; Voigt K D
SOURCE: Acta endocrinologica. Supplementum, (1971) 152 28.
Journal code: 0370313. ISSN: 0300-9750.
PUB. COUNTRY: Denmark
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197105
ENTRY DATE: Entered STN: 19900101
Last Updated on STN: 19900101
Entered Medline: 19710519

L10 ANSWER 17 OF 20 MEDLINE on STN
ACCESSION NUMBER: 67163728 MEDLINE
DOCUMENT NUMBER: PubMed ID: 4164949
TITLE: Plasma **testosterone** production rates in patients with prostatic cancer and benign **prostatic hypertrophy.**
AUTHOR: Isurugi K
SOURCE: Journal of urology, (1967 May) 97 (5) 903-8.
Journal code: 0376374. ISSN: 0022-5347.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 196707
ENTRY DATE: Entered STN: 19900101
Last Updated on STN: 19900101
Entered Medline: 19670728

L10 ANSWER 18 OF 20 MEDLINE on STN
ACCESSION NUMBER: 56058868 MEDLINE
DOCUMENT NUMBER: PubMed ID: 13306513
TITLE: The rationale of treating benign **prostatic hypertrophy** with combinations of **testosterone** and estrogen.
AUTHOR: GLASS S J
SOURCE: Journal of the American Geriatrics Society, (1956 Apr) 4 (4) 358-64.
Journal code: 7503062. ISSN: 0002-8614.
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: OLDMEDLINE; NONMEDLINE
OTHER SOURCE: CLML5630-14723
ENTRY MONTH: 200305
ENTRY DATE: Entered STN: 20040200
Last Updated on STN: 20040200
Entered Medline: 20030501

L10 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 8
ACCESSION NUMBER: 1955:50321 CAPLUS

DOCUMENT NUMBER: 49:50321
ORIGINAL REFERENCE NO.: 49:9804g-i
TITLE: Anaerobic glycolysis of human benign **prostatic hypertrophy** slices: inhibition by **testosterone**
AUTHOR(S): McDonald, D. F.; Latta, M. J.
CORPORATE SOURCE: Univ. Washington School of Med., Seattle
SOURCE: Journal of Applied Physiology (1948-1976) (1954), 7, 325-8
CODEN: JAPYAA; ISSN: 0021-8987
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB The QN2CO2 of 142 observations on 50 different human benign prostatic hypertrophy specimens was 4.9 ± 1.3 microliters Co2/mg. dry weight tissue/hr.; 2 specimens of known carcinoma tissue gave values of 9.4 and 10.5 microliters CO2/mg./hr. Testosterone inhibited anaerobic glycolysis, the effect being proportional to the quantity of testosterone added; at a concentration of 1.75 millimolar inhibition was 58% and was comparable to that resulting from glucose deprivation. Inhibition was sustained for periods up to 4 hrs., indicating that all of the added testosterone probably was not used. The inhibition was reversible by washing. The in vitro inhibition of anaerobic glycolysis by testosterone is in contrast to its behavior in vivo, where growth and function of the gland are stimulated.

L10 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1937:63053 CAPLUS
DOCUMENT NUMBER: 31:63053
ORIGINAL REFERENCE NO.: 31:8695d-e
TITLE: **Prostatic hypertrophy.** Studies of hormonal treatment with **testosterone** salts
AUTHOR(S): Laroche, Guy; Marsan, F.; Bompard, E.; Corcos, A.
SOURCE: Presse Medicale (1893-1971) (1937), 45, 932-6
CODEN: PRMEAI; ISSN: 0032-7867
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB The treatment consisted of 2-3 series of 12 injections giving a total of 1 to 2 g. testosterone during 6 months. As results were noted relief of frequency of urination in simple prostatism, improvement in 50% of the cases of incomplete retention and the reestablishment of voluntary nicturition in 72% of cases of complete retention.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	28.19	76.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.92	-2.92

FILE 'STNGUIDE' ENTERED AT 09:12:49 ON 28 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 25, 2005 (20050225/UP).

=> d ibib abs 1-10
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, MEDLINE' - CONTINUE? (Y)/N:y

L10 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 1998:567415 CAPLUS
DOCUMENT NUMBER: 129:270811
TITLE: Endothelin receptors in **testosterone**-induced **prostatic hypertrophy** in rats

AUTHOR(S): Auger-Pourmarin, Lydie; Roubert, Pierre; Chabrier, Pierre Etienne
CORPORATE SOURCE: Institut Henri Beaufour, Les Ulis, 91966, Fr.
SOURCE: Japanese Journal of Pharmacology (1998), 77(4), 307-310
CODEN: JJPAAZ; ISSN: 0021-5198
PUBLISHER: Japanese Pharmacological Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Endothelin receptors were characterized in rat prostate and potential modification of these receptors was investigated in prostatic hypertrophy induced by testosterone. Both ETA and ETB endothelin receptor mRNAs were detected in rat prostate, whereas binding expts. show the presence of only ETA receptors. Testosterone administration produced a 75% increase in prostate weight Although the d. of prostatic endothelin receptors was decreased from 348 fmol/mg protein in control rats to 252 fmol/mg protein in testosterone-treated animals, the total amount of receptors per prostate was unchanged. The steady-state level of ETA- and ETB-receptor mRNA was not altered by testosterone treatment. These results suggest that endothelin receptors are not affected in prostatic hypertrophy induced by testosterone.
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 1998:37373 CAPLUS
DOCUMENT NUMBER: 128:165895
TITLE: α1-Adrenoceptors in **testosterone** -induced **prostatic hypertrophy**
AUTHOR(S): Auger-Pourmarin, L.; Roubert, P.; Chabrier, P. E.
CORPORATE SOURCE: Z.A. de Courtaboeuf, 5, avenue du Canada, Institute Henri Beaufour, Les Ulis Cedex, 91966, Fr.
SOURCE: European Journal of Pharmacology (1998), 341(1), 119-126
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Modifications of rat prostatic α1-adrenoceptors were investigated in testosterone-induced prostatic hypertrophy. [3H]prazosin bound to a single class of binding sites with a dissociation constant of 57.9 pM. The greater part of the binding capacity (24.6 fmol/mg protein) was made up of chloroethylclonidine-resistant binding sites that showed high-affinity for oxymetazoline and 5-methylurapidil, and was identified as α1A-adrenoceptors. The remaining chloroethylclonidine-sensitive binding sites that showed low-affinity for oxymetazoline and 5-methylurapidil were preferentially identified as α1B-adrenoceptors. MRNA for the three α1-adrenoceptors (α1a, α1b and α1d) was detected. Testosterone administration produced a 23% decrease of α1-adrenoceptor d., likely by an increase of prostatic glandular epithelium and a decrease in the relative proportion of smooth muscle, thus of α1-adrenoceptor d. The steady state level of mRNAs for α1-adrenoceptors was not modified by testosterone treatment. These results indicate that prostate α1-adrenoceptors are not affected in the prostatic hypertrophy induced by testosterone.
REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 1991:140722 CAPLUS
DOCUMENT NUMBER: 114:140722
TITLE: Serum of patients with prostatic cancer or benign **prostatic hypertrophy** contains nonpolar **testosterone**
AUTHOR(S): Addo, Samuel B.; Holland, James F.; Kirschenbaum, Alexander; Mandeli, John; Hollander, Vincent P.
CORPORATE SOURCE: Dep. Neoplas. Dis., Mount Sinai Med. Cent., New York, NY, USA

SOURCE: Steroids (1990), 55(11), 491-4
CODEN: STEDAM; ISSN: 0039-128X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A nonpolar form of RIAable serum testosterone (NPT) was previously described which was not measured by available antitestosterone antibodies. It is detected by mild alkaline hydrolysis of the petroleum ether extract of serum and subsequent RIA. The properties of NPT are consistent with that of a fatty acid ester of testosterone or dihydrotestosterone. The serum of young males contains 1 to 3 ng/mL NPT, but it is not detected in female serum. Serum testosterone and NPT levels were determined in 36 men between 58 and 87 yr of age. Seventeen subjects with advanced prostatic cancer (NPT 1.70 ng/mL) were compared with a control group consisting of 6 patients with benign prostatic hypertrophy (BPH) and 13 patients with no prostatic disease (NPT 0.72). There was no significant difference between BPH patients and patients with no prostatic disease; the results were pooled. The concentration of NPT in prostatic cancer patients but not in controls was inversely correlated with that of testosterone. Immunoassayable testosterone was present in serum of two orchiectomized patients and, therefore, cannot derive solely from the testes.

L10 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 1983:588012 CAPLUS
DOCUMENT NUMBER: 99:188012
TITLE: The metabolism of androstenedione and **testosterone** to C19 metabolites in normal breast, breast carcinoma and benign **prostatic hypertrophy** tissue
AUTHOR(S): Perel, E.; Killinger, D. W.
CORPORATE SOURCE: Dep. Med., Univ. Toronto, Toronto, ON, M5S 1A8, Can.
SOURCE: Journal of Steroid Biochemistry (1983), 19(2), 1135-9
CODEN: JSTBBK; ISSN: 0022-4731
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Human normal breast, breast carcinoma, and benign prostatic hypertrophy tissue homogenates were incubated for 90 min in Krebs-Ringer bicarbonate buffer (pH 7.4) with ATP (3 mM) and NADPH (2.4 mM) as cofactors. The formation of C19 metabolites was 10-fold greater in prostate than in breast tissue. Androsterone [53-41-8] was the major product of androstenedione (I) [63-05-8] in both breast and prostate. The other 5α-metabolites of I identified were dihydrotestosterone (DHT) [521-18-6] and epiandrosterone [481-29-8]. The 5β-metabolite, etiocholanolone (ET10) [53-42-9], was identified in both breast and prostate following incubation with I. Using testosterone [**58-22-0**] as substrate, DHT was the major product in normal breast and benign prostatic hypertrophy tissue. Et10 was detected in breast, but not in prostate following incubation with testosterone. Aromatization was demonstrated in all incubations with breast tissue, but not in prostate. I is thus actively metabolized by both breast and prostate to 5α-reduced metabolites. Et10 is formed in both tissues, and aromatization was demonstrated only in breast tissue.

L10 ANSWER 5 OF 20 MEDLINE on STN
ACCESSION NUMBER: 81040654 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6159037

TITLE: Total and SHBG-bound **testosterone** and 5 alpha-dihydrotestosterone serum concentrations in normal elderly men and patients with benign **prostatic hypertrophy** before and after removal of the adenoma.
AUTHOR: Lukkarinen O
SOURCE: British journal of urology, (1980 Oct) 52 (5) 377-80. Journal code: 15740090R. ISSN: 0007-1331.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198101
ENTRY DATE: Entered STN: 19900316
Last Updated on STN: 19900316
Entered Medline: 19810129

AB Serum testosterone, 5 alpha-dihydrotestosterone and their binding by sex hormone binding globulin (SHBG) were quantified in 10 patients with prostatic hypertrophy, before and after retropubic prostatectomy, and in an age-matched control group. Testosterone was significantly higher in the sera of the BPH patients. The SHBG-bound testosterone and 5 alpha-dihydrotestosterone were identical in both groups, but the fraction of testosterone and 5 alpha-dihydrotestosterone not bound to SHBG was higher in the group with BPH. Therefore patients with prostatic hypertrophy are exposed to increased androgen action. Prostatectomy did not lead to significant changes in serum testosterone, 5 alpha-dihydrotestosterone or their binding to SHBG.

L10 ANSWER 6 OF 20 MEDLINE on STN
ACCESSION NUMBER: 80016054 MEDLINE
DOCUMENT NUMBER: PubMed ID: 90434
TITLE: [An urodynamic study of patients with benign **prostatic hypertrophy** treated conservatively with phytotherapy or **testosterone** (author's transl)].
Urodynamische Verlaufskontrolle bei konservativer Behandlung des Prostataadenoms mit Phytopraparat und Testosteron.
AUTHOR: Flamm J; Kiesswetter H; Englisch M
SOURCE: Wiener klinische Wochenschrift, (1979 Sep 28) 91 (18) 622-7. Journal code: 21620870R. ISSN: 0043-5325.
PUB. COUNTRY: Austria
DOCUMENT TYPE: (CLINICAL TRIAL)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: German
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197911
ENTRY DATE: Entered STN: 19900315
Last Updated on STN: 19980206
Entered Medline: 19791121

AB Conservative therapy of benign prostatic hypertrophy comprises the administration of oestrogens, gestagens, androgens and anti-androgens. Phytodrugs, which contain an extract of Sabal serrulatum or Pygeum Africana as active substance are without side effects and are, therefore, being used increasingly. 74 patients with irritable or obstructive bladder symptoms due to benign prostatic hypertrophy were treated with a phytodrug (Sabal serrulatum) or with testosterone throughout a period of three months. In group one (20 patients given phytodrugs and 10 patients given testosterone) clinical symptoms and measurements of residual urine, residual urine quotient, bladder capacity, micturition pressure and maximum urethral closure pressure were recorded at the beginning and at the end of therapy. In group two 28 patients were treated with the phytodrug in the first and third months with an intervening placebo trial lasting four weeks and 16 patients were given testosterone. Clinical symptoms and uroflow and residual urine only were charted in this group. None of the patients in either group showed an improvement in the urodynamic parameters of obstruction, but all patients felt a subjective

alleviation of their symptoms.

L10 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1979:184532 CAPLUS
DOCUMENT NUMBER: 90:184532
TITLE: Metabolism of **testosterone** in human prostatic tissue from prostatic carcinoma and benign **prostatic hypertrophy**
AUTHOR(S): Takenaka, Ikumasa; Goto, Hajime; Kohara, Hiromi
CORPORATE SOURCE: Sch. Med., Tottori Univ., Yonago, Japan
SOURCE: Yonago Acta Medica (1978), 22(2), 73-9
CODEN: YOAMAQ; ISSN: 0513-5710
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Testosterone was mainly metabolized by prostatic carcinoma tissue into Δ4-androstenedione, whereas its 5α-reduced metabolites were formed only in small amts. The inner cell mass of benign prostatic hypertropic tissue metabolized testosterone mainly to its 5α-reduced metabolites, whereas small amts. of Δ4-androstenedione were formed. The outer cell mass of benign prostatic hypertrophic tissue metabolized testosterone to both Δ4-androstenedione and its 5α-reduced metabolites. Thus, the outer cell mass showed characteristics of testosterone metabolism which were intermediate between the inner cell mass and prostatic carcinoma. The origin of prostatic carcinoma from the outer cell mass is discussed.

L10 ANSWER 8 OF 20 MEDLINE on STN
ACCESSION NUMBER: 77185031 MEDLINE
DOCUMENT NUMBER: PubMed ID: 67948
TITLE: Kinetics of 3H-**testosterone** and 3H-dihydrotestosterone metabolism in patients with benign **prostatic hypertrophy.** Effect of cyproterone acetate.
AUTHOR: Hutschenreiter G; Sinterhauf K; Altwein J E
SOURCE: European urology, (1977) 3 (2) 100-4.
Journal code: 7512719. ISSN: 0302-2838.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197707
ENTRY DATE: Entered STN: 19900314
Last Updated on STN: 19970203
Entered Medline: 19770729
AB The response of 3H-testosterone and 3H-dihydrotestosterone to the administration of cyproterone acetate (CA) over a period of 5 days was investigated. Both tracers were injected intravenously in patients with benign prostatic hypertrophy. Blood was withdrawn for up to 5 h. Benign prostatic hypertrophy tissue was obtained by transurethral resection. Nine patients served as controls. Eleven patients received 300 mg CA intramuscularly. Cyproterone acetate suppressed testosterone and FSH, but not LH. 3H-testosterone was cleared more rapidly from plasma in the patients given CA presumably due to increased metabolism in the liver. 3H-dihydrotestosterone, however, remained virtually uninfluenced. Moreover, CA did not significantly alter the 3H-testosterone and 3H-dihydrotestosterone uptake and metabolism within prostatic tissue.

L10 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 1977:69662 CAPLUS
DOCUMENT NUMBER: 86:69662
TITLE: A study of the interdependence between **prostatic hypertrophy** and disturbances in hormone balance. Preliminary report. I. Study of serum **testosterone**
AUTHOR(S): Szymanoski, J.; Baranowska, B.; Migdalska, B.; Kozlowicz, I.
CORPORATE SOURCE: Hop. Bielanski, Warsaw, Pol.
SOURCE: Journal d'Urologie et de Nephrologie (1976), 82(10-11), 827-36

CODEN: JURNAP; ISSN: 0021-8200
DOCUMENT TYPE: Journal
LANGUAGE: French
AB Using a radioimmunol. method and applying a double antibody separation technique, LH and testosterone were determined in blood serum of patients with prostatic hypertrophy. Patients with prostatic hypertrophy showed testosterone concns. several times higher than the men in the control groups. Testosterone levels in patients with considerable hypertrophy of the prostate were higher than in patients with moderate hypertrophy. Prostatectomy decreased testosterone in the serum.

L10 ANSWER 10 OF 20 MEDLINE on STN
ACCESSION NUMBER: 77088464 MEDLINE
DOCUMENT NUMBER: PubMed ID: 64267
TITLE: **Testosterone** metabolism in benign **prostatic hypertrophy**: in vivo studies of gestonorone caproate and cyproterone acetate.
AUTHOR: Orestano F; Altwein J E
SOURCE: British journal of urology, (1976 Dec) 48 (6) 485-91. Journal code: 15740090R. ISSN: 0007-1331.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: (CLINICAL TRIAL)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197703
ENTRY DATE: Entered STN: 19900313
Last Updated on STN: 19980206
Entered Medline: 19770315
AB 18 patients with obstructive benign prostatic hypertrophy were studied. A 5-day treatment with gestonorone caproate (200 mg daily and 200 mg on alternate days) and cyproterone acetate (300 mg daily) suppressed the plasma LH and serum LH levels. Subsequently, H3-testosterone was injected intravenously and its elimination from plasma and uptake and metabolism in the BPH tissue studied. The elimination of total radioactivity and H3-testosterone from plasma was not altered after the 3 treatment regimens as compared to the control group. The uptake of total radioactivity into BPH tissue and its intraprostatic metabolism particularly to dihydrotestosterone was significantly suppressed in the patients with daily injections of gestonorone. Cyproterone acetate and gestonorone caproate on alternate days did not cause this effect.

=>
=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.56	96.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.30

STN INTERNATIONAL LOGOFF AT 09:35:52 ON 28 FEB 2005